{"id":477447,"date":"2020-04-02T12:20:01","date_gmt":"2020-04-02T12:20:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477447"},"modified":"2020-04-02T12:20:01","modified_gmt":"2020-04-02T12:20:01","slug":"hemophilia-b-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-b-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_477447.html","title":{"rendered":"Hemophilia B Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Hemophilia<\/a><\/div>\n

DelveInsight has launched a new report on Hemophilia B Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Hemophilia B – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology as well as the Hemophilia B market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The Hemophilia B market report provides current treatment practices, emerging drugs, Hemophilia B market share of the individual therapies, current and forecasted Hemophilia B market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hemophilia B treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

According tothe Centers for Disease Control and Prevention, Hemophilia B <\/strong>is a genetic disorder caused by missing or defective Factor IX clotting protein. With the lack of this, the blood cannot clot properly to control bleedinglike hemophilia A, it is also inherited and is caused by a spontaneous genetic mutation in one-third of the cases. Individuals with hemophilia B do not bleed faster than unaffected individuals, they bleed longer.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

Request for :- <\/strong>free sample page<\/a><\/p>\n

Epidemiology<\/strong><\/p>\n

The Hemophilia B epidemiology division provide insights about historical and current Hemophilia B patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. <\/p>\n

Reports Key facts:- <\/strong><\/p>\n

1.  <\/strong>According to the World Federation of Hemophilia (WFH)<\/strong>, the total number of cases around the World for Hemophilia B in 2018 was 34,289.<\/p>\n

2. Centers for Disease Control and Prevention<\/strong>states Hemophilia occurs in about 1 of every 5,000 male births and Hemophilia A is about four times as common as hemophilia B, and about half of those affected have a severe form. Hemophilia affects people from all racial and ethnic groups. Additionally about 3 in 100 people with hemophilia B develop an inhibitor to the treatment product used to treat or prevent their bleeding episodes.<\/p>\n

3. As per Santoro, Cristina, et al.<\/strong>, 2018, <\/strong>the development of an inhibitor in Hemophilia B is a rare event i.e., 1.5–3% of all patients but is associated with a significant morbidity, related not only to the bleeding risk but also to the frequent occurrence of allergic reactions and nephrotic syndrome.<\/p>\n

Key companies working on Hemophilia B that are given below:-<\/strong><\/em><\/p>\n

1. <\/strong> Novo Nordisk Pharma Co.<\/em><\/p>\n

2.  <\/em><\/strong>CSL Behring Pharma Co. <\/em><\/p>\n

3.  Bioverativ Therapeutics (a Sanofi acquired company)<\/em><\/p>\n

Drug names are given below:- <\/em><\/strong><\/p>\n

1. <\/em><\/strong>Rebinyn<\/em><\/p>\n

2. Idelvion<\/em><\/p>\n

3. Alprolix<\/em><\/p>\n

Table of contents<\/a><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of Hemophilia B<\/span><\/p>\n

3. Competitive Intelligence Analysis for Hemophilia B<\/span><\/p>\n

4. Hemophilia B: Market Overview at a Glance<\/span><\/p>\n

4.1. Hemophilia B Total Market Share (%) Distribution in 2017<\/span><\/p>\n

4.2. Hemophilia B Total Market Share (%) Distribution in 2030<\/span><\/p>\n

5. Hemophilia B: Disease Background and Overview<\/span><\/p>\n

5.1. Introduction<\/span><\/p>\n

5.2. Sign and Symptoms <\/span><\/p>\n

5.3. Pathophysiology <\/span><\/p>\n

5.4. Risk Factors <\/span><\/p>\n

5.5. Diagnosis <\/span><\/p>\n

6. Patient Journey<\/span><\/p>\n

7. Hemophilia B Epidemiology and Patient Population<\/span><\/p>\n

7.1. Epidemiology Key Findings<\/span><\/p>\n

7.2. Assumptions and Rationale: 7MM<\/span><\/p>\n

7.3. Epidemiology Scenario: 7MM<\/span><\/p>\n

7.3.1. Hemophilia B Epidemiology Scenario in the 7MM (2017-2030)<\/span><\/p>\n

7.4. United States Epidemiology<\/span><\/p>\n

7.4.1. Hemophilia B Epidemiology Scenario in the United States (2017-2030)<\/span><\/p>\n

7.5. EU-5 Country-wise Epidemiology<\/span><\/p>\n

7.5.1. Germany Epidemiology<\/span><\/p>\n

7.5.1.1. Hemophilia B Epidemiology Scenario in Germany (2017-2030)<\/span><\/p>\n

7.5.2. France Epidemiology<\/span><\/p>\n

7.5.2.1. Hemophilia B Epidemiology Scenario in France (2017-2030)<\/span><\/p>\n

7.5.3. Italy Epidemiology<\/span><\/p>\n

7.5.3.1. Hemophilia B Epidemiology Scenario in Italy (2017-2030)<\/span><\/p>\n

7.5.4. Spain Epidemiology<\/span><\/p>\n

7.5.4.1. Hemophilia B Epidemiology Scenario in Spain (2017-2030)<\/span><\/p>\n

7.5.5. United Kingdom Epidemiology<\/span><\/p>\n

7.5.5.1. Hemophilia B Epidemiology Scenario in the United Kingdom (2017-2030)<\/span><\/p>\n

7.5.6. Japan Epidemiology<\/span><\/p>\n

7.5.6.1. Hemophilia B Epidemiology Scenario in Japan (2017-2030)<\/span><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

8.1. Hemophilia B Treatment and Management<\/span><\/p>\n

8.2. Hemophilia B Treatment Algorithm <\/span><\/p>\n

9. Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Hemophilia B Treatment<\/span><\/p>\n

11. Marketed Products<\/span><\/p>\n

11.1. List of Marketed Products in the 7MM<\/span><\/p>\n

11.2. Drug Name: Company Name<\/span><\/p>\n

11.2.1. Product Description<\/span><\/p>\n

11.2.2. Regulatory Milestones<\/span><\/p>\n

11.2.3. Other Developmental Activities<\/span><\/p>\n

11.2.4. Pivotal Clinical Trials<\/span><\/p>\n

11.2.5. Summary of Pivotal Clinical Trial<\/span><\/p>\n

List to be continued in report<\/span><\/p>\n

12. Emerging Therapies<\/span><\/p>\n

12.1. Key Cross<\/span><\/p>\n

12.2. Drug Name: Company Name<\/span><\/p>\n

12.2.1. Product Description<\/span><\/p>\n

12.2.2. Other Developmental Activities<\/span><\/p>\n

12.2.3. Clinical Development<\/span><\/p>\n

12.2.4. Safety and Efficacy<\/span><\/p>\n

12.2.5. Product Profile<\/span><\/p>\n

List to be continued in report<\/span><\/p>\n

13. Hemophilia B: Seven Major Market Analysis<\/span><\/p>\n

13.1. Key Findings<\/span><\/p>\n

13.2. Hemophilia B Market Size in 7MM<\/span><\/p>\n

13.3. Hemophilia B Market Size by Therapies in the 7MM<\/span><\/p>\n

14. Attribute analysis<\/span><\/p>\n

15. 7MM: Market Outlook<\/span><\/p>\n

15.1. United States: Market Size<\/span><\/p>\n

15.1.1. Hemophilia B Total Market Size in the United States<\/span><\/p>\n

15.1.2. Hemophilia B Market Size by Therapies in the United States<\/span><\/p>\n

15.2. EU-5 countries: Market Size and Outlook<\/span><\/p>\n

15.3. Germany Market Size<\/span><\/p>\n

15.3.1. Hemophilia B Total Market Size in Germany<\/span><\/p>\n

15.3.2. Hemophilia B Market Size by Therapies in Germany<\/span><\/p>\n

15.4. France Market Size<\/span><\/p>\n

15.4.1. Hemophilia B Total Market Size in France<\/span><\/p>\n

15.4.2. Hemophilia B Market Size by Therapies in France<\/span><\/p>\n

15.5. Italy Market Size<\/span><\/p>\n

15.5.1. Hemophilia B Total Market Size in Italy<\/span><\/p>\n

15.5.2. Hemophilia B Market Size by Therapies in Italy<\/span><\/p>\n

15.6. Spain Market Size<\/span><\/p>\n

15.6.1. Hemophilia B Total Market Size in Spain<\/span><\/p>\n

15.6.2. Hemophilia B Market Size by Therapies in Spain<\/span><\/p>\n

15.7. United Kingdom Market Size<\/span><\/p>\n

15.7.1. Hemophilia B Total Market Size in the United Kingdom<\/span><\/p>\n

15.7.2. Hemophilia B Market Size by Therapies in the United Kingdom<\/span><\/p>\n

15.8. Japan Market Outlook<\/span><\/p>\n

15.8.1. Japan Market Size<\/span><\/p>\n

15.8.2. Hemophilia B Total Market Size in Japan<\/span><\/p>\n

15.8.3. Hemophilia B Market Size by Therapies in Japan<\/span><\/p>\n

16. Access and Reimbursement Overview of Hemophilia B<\/span><\/p>\n

17. KOL Views<\/span><\/p>\n

18. Market Drivers<\/span><\/p>\n

19. Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

20.1. Bibliography<\/span><\/p>\n

20.2. Report Methodology<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

23. About DelveInsight<\/span><\/p>\n

Why should you buy this report?<\/strong><\/p>\n